GlassScriptPhysician profile
Joshua A Terry
NPI 1124864582
$1,215.24
in general payments reported to CMS, 2019-2025
17 companies · $1,201 in 2025
The $1,201 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $13.77 · 2025: $1,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calyxo, INC. | $306.49 | 2025 | Cvac Aspiration System |
| Medtronic, INC. | $258.92 | 2025 | Interstim, Altaviva |
| Antares Pharma, INC. | $134.54 | 2025 | Xyosted |
| Procept Biorobotics Corporation | $121.03 | 2025 | |
| Sumitomo Pharma America, INC. | $74.90 | 2025 | Gemtesa |
| Urogen Pharma, INC. | $57.72 | 2025 | |
| 180 Medical, INC. | $51.10 | 2025 | |
| Boston Scientific Corporation | $36.37 | 2025 | Ams 700, Axonics |
| Progenics Pharmaceuticals, INC. | $24.55 | 2025 | |
| Pfizer INC. | $24.17 | 2025 | |
| Verity Pharmaceuticals INC. | $21.00 | 2025 | Trelstar |
| Pharmaand Gmbh | $20.37 | 2025 | Rubraca |
| Tolmar, INC. | $20.37 | 2025 | Rubraca, Eligard |
| Janssen Biotech, INC. | $19.57 | 2025 | Erleada |
| Abbvie INC. | $15.30 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $15.07 | 2025 | |
| Coloplast Corp | $13.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.